OBI Pharma Inc (台灣浩鼎) yesterday said it is to give an oral presentation about its new breast cancer vaccine, OBI-822, at the annual meeting of the American Society of Clinical Oncology (ASCO) in June.
The company, which received a notice from ASCO late on Wednesday, said ASCO is among the world’s largest and most influential professional organizations representing physicians of all oncology specialties providing care for cancer patients.
With more than 40,000 members, the organization reviews about 5,800 submissions each year, and OBI Pharma’s OBI-822 is among only 3.8 percent of submissions that have been selected for an oral presentation this year, the company said.
However, OBI Pharma chairman Michael Chang (張念慈) said that ASCO’s selection has little commercial implication for the company’s new treatment.
“ASCO’s selection is by no means an endorsement for the new drug, and will not affect the progress of ongoing clinical trials and regulatory approval, apart from a much-needed boost to morale among our employees,” Chang said at a press conference.
OBI Pharma has been embroiled in controversy since Feb. 21, when it announced that the results of its second and third-phase clinical trials of OBI-822 showed “no statistical significance.”
Since then, OBI Pharma shares have plummeted by nearly 40 percent from this year’s high of NT$719 on Feb. 19 to NT$351 at the end of Wednesday’s session.
The shares were suspended for trading on the Taipei Exchange to conform with regulatory guidelines at a time of disclosing material information.
Academia Sinica President Wong Chi-huey (翁啟惠), a close collaborator with the company, has also come under fire since it was revealed that his daughter, Wong Yu-shioh (翁郁秀), had sold a portion of her holdings in OBI Pharma on Feb. 18, just before prices went spiraling downward.
The Chinese-language Apple Daily yesterday reported that Wong Chi-huey had authorized the stock sale with his daughter’s stock broker at E.Sun Securities Co (玉山證券).
Regarding the allegations, Chang said that the company employs industry-standard protocols, where clinical trial information is handled and compartmentalized by external organizations.
“There were no instances of information leakage, and the allegations of insider trading using non-public information are unfounded,” Chang said, adding that Wong Chi-huey did not know of the discouraging clinical trial results until about two hours before the company held a press conference on Feb. 21.
However, Chang was unable to explain how Wong Chi-huey was able to authorize the stock sale on behalf of his daughter.
Wong Chi-huey had previously pledged that he did not hold any biotechnology stock positions.
“The company had instructed board members, managers and employees to halt all stock trades for one month prior to Feb. 21, but we had failed to include Wong Chi-huey and the company regrets the oversight,” Chang said.
CALL FOR SUPPORT: President William Lai called on lawmakers across party lines to ensure the livelihood of Taiwanese and that national security is protected President William Lai (賴清德) yesterday called for bipartisan support for Taiwan’s investment in self-defense capabilities at the christening and launch of two coast guard vessels at CSBC Corp, Taiwan’s (台灣國際造船) shipyard in Kaohsiung. The Taipei (台北) is the fourth and final ship of the Chiayi-class offshore patrol vessels, and the Siraya (西拉雅) is the Coast Guard Administration’s (CGA) first-ever ocean patrol vessel, the government said. The Taipei is the fourth and final ship of the Chiayi-class offshore patrol vessels with a displacement of about 4,000 tonnes, Lai said. This ship class was ordered as a result of former president Tsai Ing-wen’s (蔡英文) 2018
‘SECRETS’: While saying China would not attack during his presidency, Donald Trump declined to say how Washington would respond if Beijing were to take military action US President Donald Trump said that China would not take military action against Taiwan while he is president, as the Chinese leaders “know the consequences.” Trump made the statement during an interview on CBS’ 60 Minutes program that aired on Sunday, a few days after his meeting with Chinese President Xi Jinping (習近平) in South Korea. “He [Xi] has openly said, and his people have openly said at meetings, ‘we would never do anything while President Trump is president,’ because they know the consequences,” Trump said in the interview. However, he repeatedly declined to say exactly how Washington would respond in
WARFARE: All sectors of society should recognize, unite, and collectively resist and condemn Beijing’s cross-border suppression, MAC Minister Chiu Chui-cheng said The number of Taiwanese detained because of legal affairs by Chinese authorities has tripled this year, as Beijing intensified its intimidation and division of Taiwanese by combining lawfare and cognitive warfare, the Mainland Affairs Council (MAC) said yesterday. MAC Minister Chiu Chui-cheng (邱垂正) made the statement in response to questions by Democratic Progressive Party (DPP) Legislator Puma Shen (沈柏洋) about the government’s response to counter Chinese public opinion warfare, lawfare and psychological warfare. Shen said he is also being investigated by China for promoting “Taiwanese independence.” He was referring to a report published on Tuesday last week by China’s state-run Xinhua news agency,
‘ADDITIONAL CONDITION’: Taiwan will work with like-minded countries to protect its right to participate in next year’s meeting, the foreign ministry said The US will “continue to press China for security arrangements and protocols that safeguard all participants when attending APEC meetings in China,” a US Department of State spokesperson said yesterday, after Beijing suggested that members must adhere to its “one China principle” to participate. “The United States insists on the full and equal participation of all APEC member economies — including Taiwan — consistent with APEC’s guidelines, rules and established practice, as affirmed by China in its offer to host in 2026,” the unnamed spokesperson said in response to media queries about China putting a “one China” principle condition on Taiwan’s
RSS